Pharma Focus Asia

Fluor Corporation Invests US$725 million to Open New Manufacturing Facility

Introduction:

Fluor Corporation plans to open new oligonucleotide therapeutics manufacturing facility. The new facility will be located in Colorado, USA.

Features:

The manufacturing facility laid at 275,000 square-foot will house two manufacturing lines to double manufacturing capability.

The new facility under construction will handle the synthesis, purification, and lyophilisation of custom nucleic acids (also known as oligonucleotides or oligos).

The new state-of-the-art engineering facility features advanced automation, water reduction strategies, and solvent capturing to optimise cost and construction. These improvements enable to fast-track the project and support global customers' needs by getting products to market faster.

The construction of the project is expected to be complete by 2026.

Specifications:

NameFluor Corporation
TypeNew Construction
BudgetUS$725 million
Year2026
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?